PMC

PMC, the HNX-listed pharmaceutical firm, saw its stock drop nearly 10% after a nationwide recall of its Natri clorid 0.9% eye drop product due to a clarity quality failure. The recall, ordered by the Lam Dong Department of Health, affects a single batch and is classified as a Level 3 violation. While the financial impact appears limited, the event adds pressure on a stock already in a downtrend from its December 2025 peak.

PMC had a batch of Natri clorid 0.9% eye drops recalled nationwide by the Drug Administration of Vietnam for failing quality standards (clarity index). The stock dropped 0.72% on the day and has lost 33% from its December 2025 peak. The company previously paid a 70 million VND fine for similar violations, raising governance concerns.